MX2015006955A - Prueba de diagnostico molecular para cancer. - Google Patents
Prueba de diagnostico molecular para cancer.Info
- Publication number
- MX2015006955A MX2015006955A MX2015006955A MX2015006955A MX2015006955A MX 2015006955 A MX2015006955 A MX 2015006955A MX 2015006955 A MX2015006955 A MX 2015006955A MX 2015006955 A MX2015006955 A MX 2015006955A MX 2015006955 A MX2015006955 A MX 2015006955A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- angiogenesis
- present
- test
- molecular diagnostic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 238000002405 diagnostic procedure Methods 0.000 title abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 3
- 230000004043 responsiveness Effects 0.000 abstract 2
- 238000011285 therapeutic regimen Methods 0.000 abstract 2
- 239000004037 angiogenesis inhibitor Substances 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000003827 upregulation Effects 0.000 abstract 1
- 230000006459 vascular development Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Databases & Information Systems (AREA)
- Evolutionary Computation (AREA)
- Bioethics (AREA)
- Epidemiology (AREA)
- Software Systems (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732761P | 2012-12-03 | 2012-12-03 | |
| PCT/GB2013/053202 WO2014087156A1 (en) | 2012-12-03 | 2013-12-03 | Molecular diagnostic test for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015006955A true MX2015006955A (es) | 2016-01-25 |
Family
ID=49780086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006955A MX2015006955A (es) | 2012-12-03 | 2013-12-03 | Prueba de diagnostico molecular para cancer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11091809B2 (enExample) |
| EP (1) | EP2925885B1 (enExample) |
| JP (1) | JP2015536667A (enExample) |
| KR (1) | KR20150090246A (enExample) |
| CN (1) | CN105102631A (enExample) |
| AU (1) | AU2013353839A1 (enExample) |
| CA (1) | CA2893033A1 (enExample) |
| HK (1) | HK1214633A1 (enExample) |
| IL (1) | IL239196A0 (enExample) |
| MX (1) | MX2015006955A (enExample) |
| SG (1) | SG11201504023SA (enExample) |
| WO (1) | WO2014087156A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10260097B2 (en) | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| HK1214633A1 (zh) | 2012-12-03 | 2016-07-29 | Almac Diagnostics Limited | 癌症的分子诊断测试 |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| GB201409479D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| GB201409476D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular subtype for use in prognosis |
| GB201409478D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Pro-angiogenic signature |
| JP2017523776A (ja) * | 2014-07-14 | 2017-08-24 | ジェネンテック， インコーポレイテッド | 膠芽腫の診断方法及びその治療用組成物 |
| CN104212440B (zh) * | 2014-09-03 | 2016-03-30 | 无锡艾德美特生物科技有限公司 | 一类喹唑啉类荧光探针及其制备和应用 |
| EP3237639A2 (en) * | 2014-12-23 | 2017-11-01 | Genentech, Inc. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
| AU2017211247B2 (en) * | 2016-01-25 | 2023-03-09 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker |
| WO2017181079A2 (en) * | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
| CA3024465A1 (en) * | 2016-05-17 | 2017-11-23 | Genentech, Inc. | Stromal gene signatures for diagnosis and use in immunotherapy |
| WO2018124153A1 (ja) | 2016-12-28 | 2018-07-05 | 公益財団法人がん研究会 | 抗ｖｅｇｆｒ－２抗体医薬品の治療効果を予測するバイオマーカー、検査方法、及び検査キット |
| MX2019010295A (es) | 2017-03-01 | 2019-11-21 | Genentech Inc | Métodos de diagnóstico y terapéuticos para el cáncer. |
| CN111033631B (zh) * | 2017-06-13 | 2024-03-12 | 波士顿基因公司 | 用于生成分子功能谱、对其进行可视化和分类的系统和方法 |
| AU2018301704A1 (en) * | 2017-07-14 | 2020-03-05 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
| CN107621545B (zh) * | 2017-07-26 | 2019-10-11 | 东南大学 | Bicc1蛋白对精神疾病诊断的新用途 |
| WO2019074920A1 (en) * | 2017-10-10 | 2019-04-18 | Oncocyte Corporation | METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER |
| WO2019112966A2 (en) * | 2017-12-04 | 2019-06-13 | Nantomics, Llc | Subtyping of tnbc and methods |
| CN108524937B (zh) * | 2018-05-11 | 2020-05-05 | 中南大学湘雅三医院 | Mrvi1-as1作为靶位点在制备治疗鼻咽癌紫杉醇化疗增敏药物中的应用 |
| KR102636164B1 (ko) * | 2018-08-31 | 2024-02-13 | 세노 메디컬 인스투르먼츠 인코포레이티드 | 초음파 및/또는 광음향 특징들에 기반한 암 분자 아형들을 결정하는 방법 및 시스템 |
| CN109585011A (zh) * | 2018-10-26 | 2019-04-05 | 朱海燕 | 胸痛患者的病症诊断方法及机器可读存储介质 |
| CA3138566A1 (en) * | 2019-04-30 | 2020-11-05 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy |
| CN110358827A (zh) * | 2019-07-09 | 2019-10-22 | 中国人民解放军第四军医大学 | Vmp1基因在病理诊断胶质母细胞瘤中的应用及其试剂盒的制备 |
| WO2021034091A1 (ko) * | 2019-08-19 | 2021-02-25 | 재단법인 아산사회복지재단 | 교모세포종의 진단 방법 |
| IT201900023946A1 (it) * | 2019-12-13 | 2021-06-13 | Complexdata S R L | Metodo per determinare una prognosi di sopravvivenza a lungo termine di pazienti di cancro al seno, sulla base di algoritmi che modellizzano reti biologiche |
| CN111105843B (zh) * | 2019-12-31 | 2023-07-21 | 杭州纽安津生物科技有限公司 | 一种hlai型分子与多肽的亲和力预测方法 |
| CN111735949B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN112266961B (zh) * | 2020-10-29 | 2023-05-12 | 中山大学附属第六医院 | Tsg-6基因在预测结直肠癌转移及预后方面的应用 |
| CN112592397B (zh) * | 2020-12-31 | 2022-08-30 | 上海市胸科医院 | Ccdc80来源的多肽及其用途 |
| CN113035298B (zh) * | 2021-04-02 | 2023-06-20 | 南京信息工程大学 | 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法 |
| KR102897399B1 (ko) * | 2021-04-12 | 2025-12-08 | 연세대학교 산학협력단 | 유방암 진단을 위한 신규 바이오마커 |
| US20250266162A1 (en) * | 2021-05-13 | 2025-08-21 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of targeted multi-panel approach and tiered a.i. use for differential diagnosis and prognosis |
| CN116243003B (zh) * | 2023-02-20 | 2025-12-09 | 东莞市滨海湾中心医院(东莞市太平人民医院、东莞市第五人民医院) | Smox在制备结直肠癌诊断或预后预测产品中的应用 |
| CN116482367A (zh) * | 2023-05-04 | 2023-07-25 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | 一种联合mSEPT9检测和生物标志物的结直肠癌检测方法 |
| CN116519954B (zh) * | 2023-06-28 | 2023-10-27 | 杭州广科安德生物科技有限公司 | 一种结直肠癌检测模型构建方法、系统及生物标志物 |
| CN117089621B (zh) * | 2023-09-28 | 2024-06-25 | 上海爱谱蒂康生物科技有限公司 | 生物标志物组合及其在预测结直肠癌疗效中的应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| JP2775346B2 (ja) | 1992-04-03 | 1998-07-16 | アプライド バイオシステムズ，インコーポレイテッド | プローブ構成物および方法 |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
| WO1997027317A1 (en) | 1996-01-23 | 1997-07-31 | Affymetrix, Inc. | Nucleic acid analysis techniques |
| US6946442B2 (en) | 1994-11-30 | 2005-09-20 | Asif Syed Ahmed | Method of hastening cervical ripening |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| WO2004005883A2 (en) | 2002-07-02 | 2004-01-15 | The Johns Hopkins University | Secreted and cytoplasmic tumor endothelial markers |
| US6998234B2 (en) | 2000-11-03 | 2006-02-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells |
| WO2003096981A2 (en) | 2002-05-15 | 2003-11-27 | Seul, Kyung, Hwan | Method of modulating angiogenesis |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| WO2004108896A2 (en) * | 2003-06-03 | 2004-12-16 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors |
| JP4682152B2 (ja) | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| US20080113874A1 (en) | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| CA2563074C (en) | 2004-04-09 | 2014-05-20 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| US20060204951A1 (en) * | 2004-04-26 | 2006-09-14 | Judah Folkman | Platelet biomarkers for the detection of disease |
| BRPI0511088A (pt) | 2004-05-14 | 2007-12-26 | Monica Nister | identificação e caracterização de um subconjunto de glioblastomas sensìveis ao tratamento com imatinib |
| AU2005263972A1 (en) | 2004-07-23 | 2006-01-26 | Astrazeneca Ab | Method of predicting the responsiveness of a tumor to erbB receptor drugs |
| JP2008518610A (ja) | 2004-11-03 | 2008-06-05 | アルマック ダイアグノスティックス リミテッド | トランスクリプトームマイクロアレイ技法およびそれを使用する方法 |
| US7862995B2 (en) * | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| WO2006101925A2 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US20080305962A1 (en) | 2005-07-29 | 2008-12-11 | Ralph Markus Wirtz | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies |
| AU2006292278B2 (en) | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US7919261B2 (en) | 2005-12-05 | 2011-04-05 | Merck Sharp & Dohme Corp. | Methods for predicting treatment response based on the expression profiles of protein and transcription biomarkers |
| US20070128636A1 (en) | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
| JP2009524438A (ja) | 2006-01-27 | 2009-07-02 | トライパス イメージング インコーポレイテッド | 卵巣癌を有する可能性の高い患者を同定するための方法およびそのための組成物 |
| CA2639070A1 (en) | 2006-04-13 | 2007-11-01 | Oncomethylime Sciences S.A. | Novel tumour suppressor |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| EP2074226A2 (en) * | 2006-09-19 | 2009-07-01 | Novartis AG | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| NZ582941A (en) | 2007-08-13 | 2012-05-25 | Almac Diagnostics Ltd | A 3' -based sequencing approach for microarray manufacture |
| US20090092603A1 (en) | 2007-09-25 | 2009-04-09 | Bamdad Cynthia C | Early diagnosis and treatment of drug resistance in muc1-positive cancer |
| NZ562237A (en) | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| WO2009061800A2 (en) * | 2007-11-09 | 2009-05-14 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
| WO2009076229A2 (en) | 2007-12-07 | 2009-06-18 | Oregon Health & Science University | Methods to determine if a subject will respond to a bcr-abl inhibitor |
| US8507656B2 (en) * | 2008-01-28 | 2013-08-13 | Medimmune Limited | Stabilized angiopoietin-2 antibodies and uses thereof |
| US8114593B2 (en) | 2008-03-12 | 2012-02-14 | University Of Medicine And Dentistry Of New Jersey | Cancer biomarker genes and gene products and methods for using the same |
| WO2009149297A1 (en) | 2008-06-04 | 2009-12-10 | The Arizona Board Regents, On Behalf Of The University Of Arizona | Diffuse large b-cell lymphoma markers and uses therefor |
| ES2552937T3 (es) | 2008-06-06 | 2015-12-03 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Factor de predicción de supervivencia para linfoma difuso de células B grandes |
| CA2730614A1 (en) | 2008-07-16 | 2010-01-21 | Dana-Farber Cancer Institute | Signatures and pcdeterminants associated with prostate cancer and methods of use thereof |
| JP5606438B2 (ja) | 2008-07-23 | 2014-10-15 | エフ．ホフマン−ラ ロシュ アーゲー | 抗血管新生療法を受容可能な被験体の同定 |
| DK2368118T3 (da) | 2008-12-23 | 2013-11-25 | Merck Patent Gmbh | Biomarkører til inhibitorer med anti-angiogen aktivitet |
| WO2010088688A2 (en) | 2009-02-02 | 2010-08-05 | Biotheranostics, Inc. | Diagnosis of in situ and invasive breast cancer |
| EP2425020A4 (en) | 2009-05-01 | 2016-04-20 | Genomic Health Inc | GENE EXPRESSION PROFILE GORITHM AND TEST OF PROBABILITY OF REPRODUCTION OF COLORECTAL CANCER AND RESPONSE TO CHEMOTHERAPY |
| US7615353B1 (en) * | 2009-07-06 | 2009-11-10 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| KR101557545B1 (ko) * | 2009-09-17 | 2015-10-06 | 에프. 호프만-라 로슈 아게 | 암 환자에서 진단 용도를 위한 방법 및 조성물 |
| EP2975399B1 (en) | 2010-09-15 | 2022-05-11 | Almac Diagnostic Services Limited | Molecular diagnostic test for cancer |
| WO2012054284A2 (en) * | 2010-10-20 | 2012-04-26 | University Of Tennessee Research Foundation | Interferon gene signature and methods of use thereof |
| WO2012052757A1 (en) | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
| AU2011352167A1 (en) | 2010-12-28 | 2013-07-11 | Caris Mpi, Inc. | Molecular profiling for cancer |
| US10260097B2 (en) * | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| CA2862835A1 (en) | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
| EP2667193A1 (en) | 2012-05-23 | 2013-11-27 | Université d'Aix-Marseille | MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients |
| HK1214633A1 (zh) | 2012-12-03 | 2016-07-29 | Almac Diagnostics Limited | 癌症的分子诊断测试 |
-
2013
- 2013-12-03 HK HK16102633.1A patent/HK1214633A1/zh unknown
- 2013-12-03 AU AU2013353839A patent/AU2013353839A1/en not_active Abandoned
- 2013-12-03 KR KR1020157017703A patent/KR20150090246A/ko not_active Withdrawn
- 2013-12-03 WO PCT/GB2013/053202 patent/WO2014087156A1/en not_active Ceased
- 2013-12-03 CN CN201380071098.3A patent/CN105102631A/zh active Pending
- 2013-12-03 JP JP2015544542A patent/JP2015536667A/ja active Pending
- 2013-12-03 CA CA2893033A patent/CA2893033A1/en not_active Abandoned
- 2013-12-03 EP EP13808178.1A patent/EP2925885B1/en active Active
- 2013-12-03 MX MX2015006955A patent/MX2015006955A/es unknown
- 2013-12-03 US US14/649,421 patent/US11091809B2/en not_active Expired - Fee Related
- 2013-12-03 SG SG11201504023SA patent/SG11201504023SA/en unknown
-
2015
- 2015-06-03 IL IL239196A patent/IL239196A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL239196A0 (en) | 2015-07-30 |
| WO2014087156A1 (en) | 2014-06-12 |
| SG11201504023SA (en) | 2015-06-29 |
| EP2925885A1 (en) | 2015-10-07 |
| US20160002732A1 (en) | 2016-01-07 |
| US11091809B2 (en) | 2021-08-17 |
| HK1214633A1 (zh) | 2016-07-29 |
| CN105102631A (zh) | 2015-11-25 |
| CA2893033A1 (en) | 2014-06-12 |
| JP2015536667A (ja) | 2015-12-24 |
| EP2925885B1 (en) | 2020-02-05 |
| KR20150090246A (ko) | 2015-08-05 |
| AU2013353839A1 (en) | 2015-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1214633A1 (zh) | 癌症的分子诊断测试 | |
| SG195208A1 (en) | Molecular diagnostic test for cancer | |
| MY166040A (en) | Molecular diagnostic test for cancer | |
| MX2016003016A (es) | Pruebas diagnosticas moleculares para cancer pulmonar. | |
| BR112016004305A2 (pt) | métodos diagnósticos e composições para tratamento de glioblastoma | |
| BR112014024219A8 (pt) | Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit | |
| MX356802B (es) | Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf. | |
| WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
| BR112013006683A2 (pt) | diagnóstico de câncer de mama | |
| BR112012017084A2 (pt) | métodos para previsão de resposta de câncer de mama triplo-negativo à terapia | |
| ECSP13012461A (es) | Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor | |
| BR112016021383A2 (pt) | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo | |
| MX2016002987A (es) | Biomarcadores de expresion de genes con sensibilidad a laquinimod. | |
| BR112015001898A2 (pt) | sistema para identificar artefatos de movimentação; e método para identificar artefatos de movimentação | |
| BR112015020078A8 (pt) | método para aumentar uma experiência de jogo e dispositivo de monitoramento de atividade física | |
| AR088083A1 (es) | USO DE ANTICUERPOS DE UNION A IL-1b | |
| MX343801B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama. | |
| WO2014036387A3 (en) | Methods for diagnosis and treatment of cancer | |
| WO2013025952A3 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
| BR112015003046A2 (pt) | sistema de neurofeedback, processador de sinal para determinação de uma característica do sinal do sinal do biofeedback medido, método para provisão de um usuário com o neurofeedback e programa de computador. | |
| SI2900279T1 (sl) | GRPR-antagonisti za detekcijo, diagnozo in zdravljenje GRPR-pozitivnega raka | |
| MX339427B (es) | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico. | |
| PH12015500252A1 (en) | Niclosamide for the treatment of solid tumors | |
| EP3495502A3 (en) | Biomarkers for premature birth | |
| AR089067A1 (es) | Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama |